Lifecare ASA - Director's Dealing 2026

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement by Lifecare ASA (the

"Company") on 2 March 2026 regarding the commencement of the exercise period

for Warrants Series 1 issued in connection with the partially underwritten

rights issue completed in January 2026.

Each Warrant Series 1 entitles the holder to subscribe for one new share in

the Company at an exercise price of NOK 0.3342 per share.

The exercise period for Warrants Series 1 commenced on 2 March 2026 and

expires at 16:30 (CET) today, 13 March 2026. Warrants that are not exercised

to subscribe for new shares before 16:30 (CET) today, 13 March 2026, will have

no value and will lapse without compensation to the holder. Holders of

warrants who do not exercise their warrants may experience dilution of their

shareholding in the Company.

The Company has been informed that Hannibal Invest AS, a company closely

associated with Hans Hekland, board member and primary insider of Lifecare

ASA, has exercised 90,000 Warrants Series 1 for the subscription of 90,000 new

shares in the Company at a price of NOK 0.3342 per share.

Following this transaction, Hannibal Invest AS holds 958,158 shares, 0

Warrants Series 1 and 705,196 Warrants Series 2 in the Company.

Subject to timely payment of the aggregate subscription amount for the new

shares issued upon exercise of Warrants Series 1, the Company expects that the

share capital increase will be registered with the Norwegian Register of

Business Enterprises on or about 25 March 2026, and that the new shares will

be delivered to the VPS accounts of the subscribers on or about 26 March 2026.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-03-13 08:48 CET.

AI assistant